𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The safety, efficacy and pharmacokinetics of peginterferon Alfa-2a (40KD) in children with chronic hepatitis C

✍ Scribed by Schwarz, Kathleen B.; Mohan, Parvathi; Narkewicz, Michael; Molleston, Jean P.; Te, Helen S.; Hu, Sylvia; Sheridan, Susan; Lamb, Matthew; Pappas, Stephen C.; Harb, George

Book ID
122617844
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
276 KB
Volume
124
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of peginterferon alf
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 500 KB πŸ‘ 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis

187 Efficacy and safety of 22 weeks of m
187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYSβ„’) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUSβ„’) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial
✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 233 KB